Document Detail


Phase II study of prolonged oral etoposide in patients with ovarian cancer refractory to or relapsing within 12 months after platinum-containing chemotherapy.
MedLine Citation:
PMID:  7993845     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PATIENTS AND METHODS: Twenty-eight patients with ovarian cancer refractory to or relapsing within 12 months after cisplatin-containing chemotherapy were treated with etoposide 50 mg/m2 daily for 21 days, followed by a 7-day break. RESULTS: Of 25 evaluable patients, 4 achieved partial responses (16%, 95% confidence interval 5%-36%) of 4, 4, 7, and 10 months' duration. The platinum treatment-free intervals for these patients were 2, 9, 7, and 10 months, respectively. Etoposide in this schedule was generally well tolerated, with myelosuppression as the major toxicity, resulting in a median dose intensity over all cycles of 83% (range 47%-100%). CONCLUSIONS: Prolonged oral etoposide is moderately active both in relapsed and platinum-refractory ovarian cancer, and a schedule of 50 mg/m2 days 1-21, every 4 weeks is fairly well tolerated in this usually heavily pretreated and elderly patient population.
Authors:
R de Wit; M E van der Burg; A van den Gaast; A Logmans; G Stoter; J Verweij
Related Documents :
22299055 - Immunohistochemical profile for unknown primary adenocarcinoma.
21992675 - The value of rituximab for the treatment of fludarabine-refractory chronic lymphocytic ...
8260235 - Adjuvant chemotherapy with a nitrosourea-based protocol in advanced malignant melanoma.
9377855 - Phase i-ii study of dose intensified chemotherapy with filgrastim and thymopentin in pa...
17932955 - Use of a chitosan-based hemostatic dressing in laparoscopic partial nephrectomy.
15616145 - Topotecan in the treatment of recurrent small cell lung cancer: an update.
Publication Detail:
Type:  Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Annals of oncology : official journal of the European Society for Medical Oncology / ESMO     Volume:  5     ISSN:  0923-7534     ISO Abbreviation:  Ann. Oncol.     Publication Date:  1994 Sep 
Date Detail:
Created Date:  1995-01-13     Completed Date:  1995-01-13     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9007735     Medline TA:  Ann Oncol     Country:  NETHERLANDS    
Other Details:
Languages:  eng     Pagination:  656-7     Citation Subset:  IM    
Affiliation:
Department of Medical Oncology, Rotterdam Cancer Institute/Dr. Daniel den Hoed Kliniek, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Cisplatin / administration & dosage
Drug Administration Schedule
Etoposide / administration & dosage*,  adverse effects,  therapeutic use
Female
Humans
Leukopenia / chemically induced
Middle Aged
Neoplasm Recurrence, Local / drug therapy*
Ovarian Neoplasms / drug therapy*
Remission Induction
Thrombocytopenia / chemically induced
Chemical
Reg. No./Substance:
15663-27-1/Cisplatin; 33419-42-0/Etoposide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesot...
Next Document:  Assessment of hypertension based on chronoengineering.